🇺🇸 FDA
Patent

US 10301304

Selective inhibitor of phosphatidylinositol 3-kinase-gamma

granted A61PA61P1/00A61P1/04

Quick answer

US patent 10301304 (Selective inhibitor of phosphatidylinositol 3-kinase-gamma) held by Vertex Pharmaceuticals Incorporated expires Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Vertex Pharmaceuticals Incorporated
Grant date
Tue May 28 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P1/00, A61P1/04, A61P1/18, A61P11/00